Immune-Mediated Therapies for Liver Cancer

被引:23
|
作者
Aravalli, Rajagopal N. [1 ]
Steer, Clifford J. [2 ]
机构
[1] Univ Minnesota, Dept Elect & Comp Engn, 200 Union St SE, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Dept Med & Genet Cell Biol & Dev, 420 Delaware St SE, Minneapolis, MN 55455 USA
来源
GENES | 2017年 / 8卷 / 02期
关键词
adaptive immunity; adoptive cell transfer; cancer vaccines; cholangiocarcinoma; hepatocellular carcinoma; immune checkpoint blockade; immunotherapy; innate immunity; tumor immunology; INDUCED KILLER-CELLS; HUMAN CHOLANGIOCARCINOMA CELLS; TUMOR-ASSOCIATED MACROPHAGES; ANTIGEN-PRESENTING CELLS; HEPATOCELLULAR-CARCINOMA; T-CELL; ANTIPLATELET THERAPY; KUPFFER CELLS; ADOPTIVE IMMUNOTHERAPY; RECURRENCE RATES;
D O I
10.3390/genes8020076
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
In recent years, immunotherapy has gained renewed interest as an alternative therapeutic approach for solid tumors. Its premise is based on harnessing the power of the host immune system to destroy tumor cells. Development of immune-mediated therapies, such as vaccines, adoptive transfer of autologous immune cells, and stimulation of host immunity by targeting tumor-evasive mechanisms have advanced cancer immunotherapy. In addition, studies on innate immunity and mechanisms of immune evasion have enhanced our understanding on the immunology of liver cancer. Preclinical and clinical studies with immune-mediated therapies have shown potential benefits in patients with liver cancer. In this review, we summarize current knowledge and recent developments in tumor immunology by focusing on two main primary liver cancers: hepatocellular carcinoma and cholangiocarcinoma.
引用
收藏
页数:20
相关论文
共 50 条
  • [41] Mesenchymal Stem Cells as Immunomodulator Therapies for Immune-Mediated Systemic Dermatoses
    Reddy, Bobby Y.
    Xu, David S.
    Hantash, Basil M.
    STEM CELLS AND DEVELOPMENT, 2012, 21 (03) : 352 - 362
  • [42] Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis
    Shelton, Edward
    Laharie, David
    Scott, Frank I.
    Mamtani, Ronac
    Lewis, James D.
    Colombel, Jean-Frederic
    Ananthakrishnan, Ashwin N.
    GASTROENTEROLOGY, 2016, 151 (01) : 97 - +
  • [43] Nitrofurantoin-induced immune-mediated lung and liver disease
    Schattner, A
    Von der Walde, J
    Kozak, N
    Sokolovskaya, N
    Knobler, H
    AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 1999, 317 (05): : 336 - 340
  • [44] Pathogenic role of environment toxins in immune-mediated liver diseases
    Stanca, Carmen M.
    Babar, Jawad
    Singal, Vineet
    Ozdenerol, Esra
    Odin, Joseph A.
    JOURNAL OF IMMUNOTOXICOLOGY, 2008, 5 (01) : 59 - 68
  • [45] Nitrofurantoin-induced immune-mediated lung and liver disease
    Milic, Rade
    Plavec, Goran
    Tufegdzic, Ivana
    Tomic, Ilija
    Sarac, Sanja
    Loncarevic, Olivera
    VOJNOSANITETSKI PREGLED, 2012, 69 (06) : 536 - 540
  • [46] Neurologic cues modulate immune-mediated liver injury and regeneration
    Woolbright, Benjamin L.
    Jaeschke, Hartmut
    HEPATOLOGY, 2016, 63 (05) : 1427 - 1429
  • [47] Immune-Mediated Neuropathies
    Mithila Fadia
    Sheetal Shroff
    Ericka Simpson
    Current Treatment Options in Neurology, 2019, 21
  • [48] Immune-mediated cholangiopathy
    Menon, Shyam
    Lekharaju, Venkata
    Terlizzo, Monica
    Sturgess, Richard
    GASTROINTESTINAL ENDOSCOPY, 2014, 80 (04) : 727 - 728
  • [49] Immune-mediated Liver Injury in Hepatitis B Virus Infection
    Oh, In Soo
    Park, Su-Hyung
    IMMUNE NETWORK, 2015, 15 (04) : 191 - 198
  • [50] Protective mechanism of bicyclol on immune-mediated liver injury in mice
    Li, Ye
    Liu, Baihe
    Yu, Yingnan
    Chen, Hui
    Hu, Jinping
    Li, Yan
    ACTA PHARMACOLOGICA SINICA, 2006, 27 : 280 - 280